Editas Medicine Banner Image

Editas Medicine

  • Ticker EDIT
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Editas Medicine Logo Image
  • 51-200 Employees
  • Based in Cambridge, Massachusetts
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomicMore medicines for a broad class of diseases.
Editas Medicine

Most Recent Annual Report

Editas Medicine
MOST RECENT 2021 Annual Report and Form 10K

Older/Archived Annual Reports